InvoCare share price rises on acquisitions announcement

The InvoCare Ltd (ASX: IVC) share price is one to watch in early trade after two new acquisitions from the Aussie funeral operator.

The InvoCare Limited (ASX: IVC) share price is one to watch this morning after the company's latest acquisition update.

a woman

What did InvoCare announce this morning?

The Aussie funeral company has entered into 2 separate sales agreements for business on the southern New South Wales coast.

InvoCare will acquire the business and assets of Batemans Bay and Moruya District Funerals as well as Broulee Memorial Gardens. The company expects to complete the purchases by the end of November.

The InvoCare share price has already lifted 1.48% in early trade to $13.68 per share.

Batemans Bay & Moruya District Funerals operates from 3 locations in Batemans Bay, Moruya and Narooma. The company performed over 400 funerals every year with annual revenue of $3 million.

Broulee Memorial Gardens performs 380 cremations per year including chapel services and memorialisation.

There was no dollar amount provided by InvoCare in the announcement regarding acquisition cost.

Where is the InvoCare share price headed this morning?

InvoCare shareholders have reacted to the news in early trade this morning, with the company's share price lifting 1.48% at time of writing. Acquirers' shares often trade heavily in the period after announcing an acquisition and this could be the case even with the smaller targets.

The company's shares also closed 0.97% higher on Monday at $13.48 per share as the S&P/ASX 200 Index (INDEXASX: XJO) hit a 3-month high.

How has the InvoCare share price performed this year?

The InvoCare share price has rocketed more than 32% higher so far this year to significantly outperform the ASX 200.

The Aussie funeral home operator has also managed to outpace fellow ASX competitor Propel Funeral Partners Ltd (ASX: PFP). The Propel share price is up 21.12% so far this year as the ASX Healthcare sector has had a strong 2019 performance.

Foolish takeaway

I'd expect to see continued movement from the InvoCare share price during morning trade following this acquisition news.

InvoCare is currently trading at a 36x earnings multiple with a tidy 2.71% net dividend yield.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has recommended InvoCare Limited and Propel Funeral Partners Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »